Letrozol Sandoz

Letrozole, the active ingredient in Letrozol Sandoz, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to treat hormone‑receptor‑positive breast cancer in postmenopausal women, including adjuvant and metastatic settings. The drug works by selectively blocking the aromatase enzyme, thereby lowering estrogen levels that can fuel tumor growth.

GNH USA supplies Letrozol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and procurement teams worldwide, with capabilities for bulk manufacturing, regulatory support and reliable logistics.

Letrozole is used in hormone‑dependent breast cancer pathways to inhibit estrogen production.

Hormone‑receptor‑positive breast cancer in postmenopausal women: reduces tumor growth and disease progression. Adjuvant treatment of early‑stage breast cancer: lowers risk of recurrence after surgery. Metastatic breast cancer in postmenopausal patients: slows disease progression and may improve survival.

Letrozole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: arthralgia or myalgia affecting daily activities. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain in the head.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatitis. - Bone fracture: increased risk due to reduced estrogen. - Pulmonary embolism: blood clot in lung arteries. - Allergic reaction: rash, swelling, or anaphylaxis.

Before initiating Letrozole therapy, several precautions and monitoring measures should be considered.

Pregnancy contraindication: drug is classified Category X and must not be used in pregnant women. Bone health monitoring: assess bone mineral density periodically due to risk of osteoporosis. Liver function: evaluate hepatic enzymes before and during treatment. Lipid profile: monitor cholesterol levels as estrogen reduction may affect lipids. Drug interactions: review concomitant medications for potential CYP3A4 inducers or inhibitors. Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Letrozole plasma levels. - Estrogen‑containing therapies (e.g., hormone replacement therapy): counteract aromatase inhibition. - Warfarin: increased anticoagulant effect leading to bleeding risk.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase Letrozole exposure. - Selective serotonin reuptake inhibitors (e.g., paroxetine): potential modest increase in side effects. - Lipid‑lowering agents (e.g., statins): monitor lipid changes.